Table 2.
Clinical and parasitological failure by day 14 and day 28
| CQ | SP | SP – AS | |
| DAY 14, n | 71 | 70 | 77 |
| ACPR | 32 (45.1) | 46 (65.7) | 76 (98.7) |
| ETF, n (%) | 18 (25.4) | 16 (22.9) | 0 (0.0) |
| LCF, n (%) | 6 (8.5) | 2 (2.9) | 0 (0.0) |
| LPF, n (%) | 15 (21.1) | 6 (8.6) | 1 (1.3) |
| TOTAL FAILURES | |||
| Per protocol, n (%) | 39 (54.9) | 24 (34.3) | 1 (1.3) |
| Intention to Treat, n (%) | 47/79 (59.5) | 31/77 (40.3) | 5/81 (6.2) |
| DAY 28 (PCR uncorrected), n | 71 | 68 | 76 |
| ACPR | 18 (25.4) | 37 (54.4) | 68 (89.5) |
| ETF, n (%) | 18 (25.4) | 16 (23.5) | 0 (0.0) |
| LCF, n (%) | 8 (11.3) | 4 (5.9) | 1 (1.3) |
| LPF, n (%) | 27 (38.0) | 11 (16.2) | 7 (9.2) |
| TOTAL FAILURES | |||
| Per protocol, n (%) | 53 (74.6) | 31 (45.6) | 8 (10.5) |
| Intention to Treat, n (%) | 61 (77.2) | 40 (51.9) | 13 (16.0) |
| DAY 28 (PCR corrected) | |||
| ACPR | 20 (28.2) | 38 (55.9) | 72 (94.7) |
| ETF, n (%) | 18 (25.4) | 16 (23.5) | 0 (0.0) |
| LCF, n (%) | 8 (11.3) | 4 (5.9) | 1 (1.3) |
| LPF, n (%) | 25 (35.2) | 10 (14.7) | 3 (3.9) |
| TOTAL FAILURES | |||
| New infections, n (%) | 2 (14.3) | 1 (14.3) | 4 (57.1) |
| Per protocol, n (%) | 51 (71.8) | 30 (44.1) | 4 (5.3) |
| Intention to Treat, n (%) | 59 (74.7) | 39 (50.6) | 9 (11.1) |
| Kaplan Meier survival analysis (%) | 71.8 | 42.0 | 5.3 |